SARS-CoV-2 Viral Proteins (SARS-CoV-2 proteins)

SARS-CoV-2 viral proteins are the structural and functional components of the severe acute respiratory syndrome coronavirus 2, the virus responsible for COVID-19. The viral proteome consists of four structural proteins—Spike (S), Envelope (E), Membrane (M), and Nucleocapsid (N)—and sixteen non-structural proteins (nsps) that are essential for the viral life cycle, including entry, replication, and assembly [1.2.1, 1.2.5]. The Spike protein mediates host cell attachment via the ACE2 receptor and is the primary target for vaccines and neutralizing monoclonal antibodies [1.1.1, 1.3.1]. Key enzymes such as the Main Protease (Mpro) and RNA-dependent RNA polymerase (RdRp) are critical for processing viral polyproteins and replicating the RNA genome, serving as the main targets for small-molecule antivirals like nirmatrelvir and remdesivir [1.1.2, 1.3.5]. Additionally, accessory proteins and the Nucleocapsid protein play vital roles in modulating the host immune response and facilitating viral pathogenesis [1.2.4, 1.4.3]. Effective therapeutic targeting of these proteins must account for rapid viral evolution and the emergence of variants that can compromise drug and vaccine efficacy [1.2.1, 1.4.2].

Other names

SARS-CoV-2 proteomeSARS-CoV-2 structural and non-structural proteinsCOVID-19 viral proteinsSARS-CoV-2 accessory proteins

Drugs targeting SARS-CoV-2 viral proteins primarily act by inhibiting essential steps in the viral life cycle. Protease inhibitors like nirmatrelvir and ensitrelvir target the Main Protease (Mpro/3CLpro), preventing the cleavage of viral polyproteins into functional non-structural proteins [1.1.3, 1.3.4]. Polymerase inhibitors such as remdesivir and molnupiravir target the RNA-dependent RNA polymerase (RdRp), leading to premature termination of RNA synthesis or lethal mutagenesis [1.1.2, 1.3.5]. Monoclonal antibodies (e.g., sotrovimab) bind to the Spike (S) protein, specifically the receptor-binding domain (RBD), to neutralize the virus by blocking its interaction with the host ACE2 receptor [1.3.1, 1.4.2]. Other experimental agents target the Envelope (E) protein's ion channel activity or the Nucleocapsid (N) protein's role in genome packaging [1.3.3, 1.4.3].